Professor of Medicine, Johns Hopkins University School of Medicine; Associate Professor of Medicine, Associate Professor Department of Molecular Microbiology and Immunology
Infectious Disease
Dr. Chloe L. Thio, MD
|
|
Give Review
Chloe L. Thio practices Infectious Disease. He went to Yale University School of Medicine. Yale University School of Medicine is a one of the best medicals schools. Yale University School of Medicine is ranked 7 in research and 57 in primary care medicine He has 1 awards "Elected Member". Chloe Thio is a published doctor as well. He has 101 publications published. The latest was: Cost-effective treatment of Candida esophagitis. He accepts Medicare.
Publications
- Highly Active Antiretroviral Therapy Mitigates Liver Disease in HIV Infection.
- Combination Antiretroviral Therapy Is Associated With Reduction in Liver Fibrosis Scores in HIV-1-Infected Subjects.
- Spontaneous Clearance of the Hepatitis C Virus Among Men Who Have Sex With Men.
- Chronic Hepatitis C Virus Infection Is Associated with Subclinical Coronary Atherosclerosis in the Multicenter AIDS Cohort Study (MACS): a Cross-Sectional Study.
- Differences in hepatitis C virus prevalence and clearance by mode of acquisition among men who have sex with men.
- Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence.
- A closer look at hepatitis C clearance in HIV controllers.
- HIV outcomes in Hepatitis B virus coinfected individuals on HAART.
- Admixture analysis of spontaneous hepatitis C virus clearance in individuals of African descent.
- Risk Factors for Fatty Liver in the Multicenter AIDS Cohort Study.
- Factors Associated with Delayed Hepatitis B Viral Suppression on Tenofovir Among HBV-HIV Coinfected Patients in the CNICS Cohort.
- Impact of maternal hepatitis B virus coinfection on mother-to-child transmission of HIV.
- Reply to Bradshaw and Danta.
- Reply to Tsai et al.
- Variants in HAVCR1 gene region contribute to hepatitis C persistence in African-Americans.
- Relation of HLA class I and II supertypes with spontaneous clearance of hepatitis C virus.
- Incident Hepatitis C Virus Infection in Men Who Have Sex With Men: A Prospective Cohort Analysis, 1984-2011.
- Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts.
- Predictors of the isolated hepatitis B core antibody pattern in HIV-infected and -uninfected men in the multicenter AIDS cohort study.
- Impact of Hepatitis C Virus on HIV Response to Antiretroviral Therapy in Nigeria.
- Characterization of HIV-HBV co-infection in a multi-national HIV-infected cohort.
- Genomics and infectious disease: a call to identify the ethical, legal and social implications for public health and clinical practice.
- HIV Monoinfection Is Associated With Increased Aspartate Aminotransferase-to-Platelet Ratio Index, a Surrogate Marker for Hepatic Fibrosis.
- Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters.
- Liver disease, HIV and aging.
- Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAART.
- KIR2DL2 Enhances Protective and Detrimental HLA Class I-Mediated Immunity in Chronic Viral Infection.
- Genetic polymorphism in IL28B is associated with spontaneous clearance of hepatitis C virus genotype 4 infection in an Egyptian cohort.
- Increased gonorrhoea and chlamydia testing did not increase case detection in an HIV clinical cohort 1999-2007.
- Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus.
- The Relation of HLA Genotype to Hepatitis C Viral Load and Markers of Liver Fibrosis in HIV-Infected and HIV-Uninfected Women.
- High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda.
- Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/sup...
- IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection.
- Review of hepatitis B therapeutics.
- IL28B and the control of hepatitis C virus infection.
- Liver disease in the HIV-infected individual.
- HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing.
- Gonorrhoea and chlamydia testing rates of HIV-infected men: low despite guidelines.
- Virology and clinical sequelae of drug-resistant HBV in HIV-HBV-coinfected patients on highly active antiretroviral therapy.
- Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus.
- Interleukin-28b: a key piece of the hepatitis C virus recovery puzzle.
- Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia.
- Genetic linkage of hepatitis B virus in peripheral blood leukocytes provides evidence for contamination.
- Host genetic determinants of spontaneous hepatitis C clearance.
- Tenofovir for the treatment of hepatitis B virus.
- Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria.
- Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.
- Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals.
- Hepatitis B and long-term HIV outcomes in coinfected HAART recipients.
- Hepatitis B and human immunodeficiency virus coinfection.
- Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease.
- Interaction between RANTES promoter variant and CCR5Delta32 favors recovery from hepatitis B.
- Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program.
- Regulatory polymorphisms in the interleukin-18 promoter are associated with hepatitis C virus clearance.
- Host genetic factors and antiviral immune responses to hepatitis C virus.
- Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance.
- Evaluation of IL10, IL19 and IL20 gene polymorphisms and chronic hepatitis B infection outcome.
- The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients.
- Diagnosis, diagnostic tests and monitoring of hepatitis B virus in monoinfected and HIV-coinfected patients.
- Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events.
- Pre-steady-state kinetic studies establish entecavir 5'-triphosphate as a substrate for HIV-1 reverse transcriptase.
- Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals.
- The HBV drug entecavir - effects on HIV-1 replication and resistance.
- Drug profile: telbivudine (Tyzeka).
- Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B.
- Clinical implications of HIV and hepatitis B co-infection in Asia and Africa.
- Treatment of HIV/HBV coinfection: clinical and virologic issues.
- Hepatitis B virus treatment in HIV-infected patients.
- A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection.
- Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence.
- Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
- Chronic hepatitis B: a critical appraisal of current approaches to therapy.
- Treatment of lamivudine-resistant hepatitis B in HIV-infected persons: is adefovir dipivoxil the answer?
- Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box.
- Mannose binding lectin genotypes influence recovery from hepatitis B virus infection.
- Association of CTLA4 polymorphism with regulatory T cell frequency.
- Treatment of chronic hepatitis B in the HIV-infected patient.
- Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection.
- Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment.
- HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).
- HLA-Cw*04 and hepatitis C virus persistence.
- Action potential conduction and sodium channel content in the optic nerve of the myelin-deficient rat.
- Correct use of the EnviroAmp PCR Legionella kit.
- Management of chronic hepatitis B in the HIV-infected patient.
- Changes in hepatitis B virus DNA levels with acute HIV infection.
- Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.
- Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection.
- HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection.
- An analysis of tumor necrosis factor alpha gene polymorphisms and haplotypes with natural clearance of hepatitis C virus infection.
- MICA and recovery from hepatitis C virus and hepatitis B virus infections.
- Ion channels in spinal cord astrocytes in vitro. III. Modulation of channel expression by coculture with neurons and neuron-conditioned medium.
- Racial differences in HLA class II associations with hepatitis C virus outcomes.
- Chronic viral hepatitis and the human genome.
- Refinements of environmental assessment during an outbreak investigation of invasive aspergillosis in a leukemia and bone marrow transplant unit.
- Screening for hepatitis C virus in human immunodeficiency virus-infected individuals.
- Paecilomyces lilacinus fungemia in an adult bone marrow transplant recipient.
- Class II HLA alleles and hepatitis B virus persistence in African Americans.
- Cost-effective treatment of Candida esophagitis.
- Differential modulation of TTX-sensitive and TTX-resistant Na+ channels in spinal cord astrocytes following activation of protein kinase C.
Schools
Yale University
Hospital Of The University Penns
Johns Hopkins University
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
- Amerigroup (Wellpoint)
- Blue Card PPO
- Blue Choice Advantage
- Blue Choice Network POS
- Blue Preferred PPO
- Cigna HMO
- Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Coventry Health Care
- Emblem Health
- First Health (Coventry Health Care) PPO
- Geisinger Health Plan
- Choice Care PPO
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Options PPO
Awards
- Elected Member
Education
-
Johns Hopkins University -
University of Pennsylvania Health System -
Yale University School of Medicine
Hospital
-
Johns Hopkins Hospital
Drug Facts
| NPI NUMBER | 1225069974 | |
| NPPES Provider LastName | THIO | |
| NPPES Provider FirstName | CHLOE | |
| NPPES Provider ZIPCode | 212870005 | |
| NPPES Provider State | MD | |
| Specialty Description | Infectious Disease | |
| Total Claim Count | 418.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1225069974 |
| Last Name Of The Provider | THIO |
| First Name Of The Provider | CHLOE |
| View All |
Similar Doctors
|
|
Dr. Michael S. Donnenberg, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeremy D. Gradon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dimitra Mitsani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Damani A. Piggott, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Allison L. Agwu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan K. Keay, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kerri A. Thom, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kawsar R. Talaat, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ann S. Vorys, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Simon Dufresne, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kelly A. Gebo, MD
This Doctor is OpenDoctor Recommended.
|